Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.

van Londen GJ, Perera S, Vujevich K, Rastogi P, Lembersky B, Brufsky A, Vogel V, Greenspan SL.

Breast Cancer Res Treat. 2011 Jan;125(2):441-6. doi: 10.1007/s10549-010-1223-2. Epub 2010 Nov 3.

2.

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.

van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R, Greenspan SL.

Bone. 2010 Mar;46(3):655-9. doi: 10.1016/j.bone.2009.10.019. Epub 2009 Oct 22.

3.

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, Sereika SM, Vogel VG.

J Clin Oncol. 2008 Jun 1;26(16):2644-52. doi: 10.1200/JCO.2007.15.2967. Epub 2008 Apr 21.

4.

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.

Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S.

Osteoporos Int. 2015 Jun;26(6):1857-64. doi: 10.1007/s00198-015-3100-7. Epub 2015 Mar 20.

5.

Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.

Elliott KM, Dent J, Stanczyk FZ, Woodley L, Coombes RC, Purohit A, Palmieri C.

Br J Surg. 2014 Jul;101(8):939-48. doi: 10.1002/bjs.9477. Epub 2014 Mar 31.

PMID:
24687409
6.

Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial.

Dias JP, Melvin D, Simonsick EM, Carlson O, Shardell MD, Ferrucci L, Chia CW, Basaria S, Egan JM.

Andrology. 2016 Jan;4(1):33-40. doi: 10.1111/andr.12126. Epub 2015 Nov 20.

7.

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R.

Lancet Oncol. 2014 Dec;15(13):1460-8. doi: 10.1016/S1470-2045(14)71035-6. Epub 2014 Nov 11. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

8.

Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group.

Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O, Labate AM.

Metabolism. 1997 Jan;46(1):5-9.

PMID:
9005961
9.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson LJ, Dawson C, Lawrence DH, Bliss JM.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370.

PMID:
17253488
10.

Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.

Baumgart J, Nilsson K, Stavreus Evers A, Kunovac Kallak T, Kushnir MM, Bergquist J, Sundström Poromaa I.

Climacteric. 2014 Feb;17(1):48-54. doi: 10.3109/13697137.2013.800039. Epub 2013 Jun 28.

PMID:
23647561
11.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson L, Lawrence D, Dawson C, Bliss J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003370. doi: 10.1002/14651858.CD003370.pub3. Review.

PMID:
19821307
12.

The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors.

Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, Ercolano E, Gross CP, Hershman D, Ligibel J, Schmitz K, Li FY, Sanft T, Irwin ML.

Obesity (Silver Spring). 2017 Feb;25(2):346-351. doi: 10.1002/oby.21729. Epub 2016 Dec 27.

PMID:
28026901
13.

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.

Napoli N, Rastelli A, Ma C, Colleluori G, Vattikuti S, Armamento-Villareal R.

Pharmacogenet Genomics. 2015 Aug;25(8):377-81. doi: 10.1097/FPC.0000000000000146.

14.

Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.

Yonehara Y, Iwamoto I, Kosha S, Rai Y, Sagara Y, Douchi T.

J Obstet Gynaecol Res. 2007 Oct;33(5):696-9.

PMID:
17845332
15.

Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.

Hubalek M, Oberguggenberger A, Beer B, Meraner V, Sztankay M, Oberacher H, Schubert B, Wildt L, Seeber B, Giesinger J, Kemmler G, Holzner B, Sperner-Unterweger B.

Clin Breast Cancer. 2014 Aug;14(4):291-6. doi: 10.1016/j.clbc.2013.12.008. Epub 2013 Dec 27.

PMID:
24468298
16.

Adiposity and sex hormones in postmenopausal breast cancer survivors.

McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y, Ballard-Barbash R.

J Clin Oncol. 2003 May 15;21(10):1961-6.

17.

The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.

Akyol M, Demir L, Alacacioglu A, Ellidokuz H, Kucukzeybek Y, Yildiz Y, Gumus Z, Bayoglu V, Yildiz I, Salman T, Varol U, Kucukzeybek B, Demir L, Dirican A, Sutcu R, Tarhan MO.

Chemotherapy. 2016;61(2):57-64. doi: 10.1159/000440944. Epub 2015 Nov 17.

PMID:
26571369
18.

Heel ultrasound can assess maintenance of bone mass in women with breast cancer.

Langmann GA, Vujevich KT, Medich D, Miller ME, Perera S, Greenspan SL.

J Clin Densitom. 2012 Jul-Sep;15(3):290-4. doi: 10.1016/j.jocd.2012.01.008. Epub 2012 Mar 16.

19.

Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.

Diorio C, Lemieux J, Provencher L, Hogue JC, Vachon E.

Breast Cancer Res Treat. 2012 Nov;136(2):573-9. doi: 10.1007/s10549-012-2278-z. Epub 2012 Oct 6.

PMID:
23053662
20.

Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.

Cao A, Zhang J, Liu X, Wu W, Liu Y, Fan Z, Zhang A, Zhou T, Fu P, Wang S, Ouyang Q, Tang J, Jiang H, Zhang X, Pang D, He J, Shi L, Wang X, Sheng Y, Mao D, Shao Z.

Health Qual Life Outcomes. 2016 Mar 24;14:51. doi: 10.1186/s12955-016-0446-2.

Supplemental Content

Support Center